204 related articles for article (PubMed ID: 21908393)
1. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.
Cox FM; Titulaer MJ; Sont JK; Wintzen AR; Verschuuren JJ; Badrising UA
Brain; 2011 Nov; 134(Pt 11):3167-75. PubMed ID: 21908393
[TBL] [Abstract][Full Text] [Related]
2. Long-term observational study of sporadic inclusion body myositis.
Benveniste O; Guiguet M; Freebody J; Dubourg O; Squier W; Maisonobe T; Stojkovic T; Leite MI; Allenbach Y; Herson S; Brady S; Eymard B; Hilton-Jones D
Brain; 2011 Nov; 134(Pt 11):3176-84. PubMed ID: 21994327
[TBL] [Abstract][Full Text] [Related]
3. Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis.
Allenbach Y; Benveniste O; Decostre V; Canal A; Eymard B; Herson S; Bloch-Queyrat C; Hogrel JY
Neuromuscul Disord; 2012 Nov; 22(11):980-6. PubMed ID: 22738680
[TBL] [Abstract][Full Text] [Related]
4. Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials.
Hogrel JY; Allenbach Y; Canal A; Leroux G; Ollivier G; Mariampillai K; Servais L; Herson S; Decostre V; Benveniste O
Neuromuscul Disord; 2014 Jul; 24(7):604-10. PubMed ID: 24857365
[TBL] [Abstract][Full Text] [Related]
5. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.
Chahin N; Engel AG
Neurology; 2008 Feb; 70(6):418-24. PubMed ID: 17881720
[TBL] [Abstract][Full Text] [Related]
6. Prognosis and prognostic factors in sporadic inclusion body myositis.
Lindberg C; Oldfors A
Acta Neurol Scand; 2012 May; 125(5):353-8. PubMed ID: 21916852
[TBL] [Abstract][Full Text] [Related]
7. Long-term determinants of muscle strength decline: prospective evidence from the 22-year mini-Finland follow-up survey.
Stenholm S; Tiainen K; Rantanen T; Sainio P; Heliövaara M; Impivaara O; Koskinen S
J Am Geriatr Soc; 2012 Jan; 60(1):77-85. PubMed ID: 22211568
[TBL] [Abstract][Full Text] [Related]
8. Limb girdle muscular dystrophy: an interval study of weakness and functional impairment.
Stübgen JP
J Clin Neuromuscul Dis; 2008 Mar; 9(3):333-40. PubMed ID: 18344714
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of limitations in activities in osteoarthritis of the hip or knee: a 3-year cohort study.
van Dijk GM; Veenhof C; Spreeuwenberg P; Coene N; Burger BJ; van Schaardenburg D; van den Ende CH; Lankhorst GJ; Dekker J;
Arch Phys Med Rehabil; 2010 Jan; 91(1):58-66. PubMed ID: 20103397
[TBL] [Abstract][Full Text] [Related]
10. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis.
Johnson LG; Collier KE; Edwards DJ; Philippe DL; Eastwood PR; Walters SE; Thickbroom GW; Mastaglia FL
J Clin Neuromuscul Dis; 2009 Jun; 10(4):178-84. PubMed ID: 19494728
[TBL] [Abstract][Full Text] [Related]
11. Spinal muscular atrophy: survival pattern and functional status.
Chung BH; Wong VC; Ip P
Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
[TBL] [Abstract][Full Text] [Related]
12. Disease course and prognostic factors of progressive muscular atrophy.
Visser J; van den Berg-Vos RM; Franssen H; van den Berg LH; Wokke JH; de Jong JM; Holman R; de Haan RJ; de Visser M
Arch Neurol; 2007 Apr; 64(4):522-8. PubMed ID: 17420313
[TBL] [Abstract][Full Text] [Related]
13. Gait patterns of patients with inclusion body myositis.
Bernhardt KA; Oh TH; Kaufman KR
Gait Posture; 2011 Mar; 33(3):442-6. PubMed ID: 21269830
[TBL] [Abstract][Full Text] [Related]
14. Update on sporadic inclusion body myositis.
Hohlfeld R
Brain; 2011 Nov; 134(Pt 11):3141-5. PubMed ID: 21964918
[No Abstract] [Full Text] [Related]
15. Hand function in 45 patients with sporadic inclusion body myositis.
Eriksson M; Lindberg C
Occup Ther Int; 2012 Jun; 19(2):108-16. PubMed ID: 22495756
[TBL] [Abstract][Full Text] [Related]
16. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.
Van der Beek NA; Hagemans ML; Reuser AJ; Hop WC; Van der Ploeg AT; Van Doorn PA; Wokke JH
Neuromuscul Disord; 2009 Feb; 19(2):113-7. PubMed ID: 19084399
[TBL] [Abstract][Full Text] [Related]
17. The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis.
Alfano LN; Lowes LP; Dvorchik I; Yin H; Maus EG; Flanigan KM; Mendell JR
Neuromuscul Disord; 2014 Mar; 24(3):222-6. PubMed ID: 24342281
[TBL] [Abstract][Full Text] [Related]
18. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients.
Santorelli FM; Sciacco M; Tanji K; Shanske S; Vu TH; Golzi V; Griggs RC; Mendell JR; Hays AP; Bertorini TE; Pestronk A; Bonilla E; DiMauro S
Ann Neurol; 1996 Jun; 39(6):789-95. PubMed ID: 8651651
[TBL] [Abstract][Full Text] [Related]
19. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis.
Askanas V; Engel WK
Curr Opin Rheumatol; 2007 Nov; 19(6):550-9. PubMed ID: 17917534
[TBL] [Abstract][Full Text] [Related]
20. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects.
Engel WK; Askanas V
Neurology; 2006 Jan; 66(2 Suppl 1):S20-9. PubMed ID: 16432141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
